JO3111B1 - ترايازولوبيريدينات مستبدلة واستخدامها كمثبطات ttk - Google Patents
ترايازولوبيريدينات مستبدلة واستخدامها كمثبطات ttkInfo
- Publication number
- JO3111B1 JO3111B1 JOP/2012/0375A JOP20120375A JO3111B1 JO 3111 B1 JO3111 B1 JO 3111B1 JO P20120375 A JOP20120375 A JO P20120375A JO 3111 B1 JO3111 B1 JO 3111B1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- ttk inhibitors
- substituted
- substituted triazolopyridines
- triazolopyridines
- Prior art date
Links
- 150000008523 triazolopyridines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات triazolopyridine مستبدلة من الصيغة العامة (I): (I) التي فيها يكون R1، R2، R3، R4، وR5 كما هم في الوصف وفي عناصر الحماية، بطريقة لتحضير المركبات المذكورة، بتركيبات دوائية (pharmaceutical compositions) واتحادات تشتمل على المركبات المذكورة، باستخدام المركبات المذكورة لتصنيع تركيبة دوائية لمعالجة أو الوقاية من مرض، بالإضافة إلى المركبات الوسطية المفيدة في تحضير المركبات المذكورة.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11193011 | 2011-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3111B1 true JO3111B1 (ar) | 2017-09-20 |
Family
ID=47427291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2012/0375A JO3111B1 (ar) | 2011-12-12 | 2012-12-11 | ترايازولوبيريدينات مستبدلة واستخدامها كمثبطات ttk |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US9663510B2 (ar) |
| EP (1) | EP2791136B1 (ar) |
| JP (1) | JP6181664B2 (ar) |
| KR (1) | KR20140105552A (ar) |
| CN (1) | CN104114552B (ar) |
| AP (1) | AP4017A (ar) |
| AR (1) | AR089143A1 (ar) |
| AU (1) | AU2012350751B2 (ar) |
| BR (1) | BR112014014184A2 (ar) |
| CA (1) | CA2858683A1 (ar) |
| CL (1) | CL2014001546A1 (ar) |
| CO (1) | CO6980657A2 (ar) |
| CR (1) | CR20140275A (ar) |
| CU (1) | CU20140068A7 (ar) |
| CY (1) | CY1116958T1 (ar) |
| DK (1) | DK2791136T3 (ar) |
| DO (1) | DOP2014000133A (ar) |
| EC (1) | ECSP14004812A (ar) |
| ES (1) | ES2550677T3 (ar) |
| GT (1) | GT201400111A (ar) |
| HR (1) | HRP20151103T1 (ar) |
| HU (1) | HUE025937T2 (ar) |
| IL (1) | IL232930A (ar) |
| JO (1) | JO3111B1 (ar) |
| MA (1) | MA35826B1 (ar) |
| MX (1) | MX2014007057A (ar) |
| PE (1) | PE20141597A1 (ar) |
| PH (1) | PH12014501319A1 (ar) |
| PL (1) | PL2791136T3 (ar) |
| PT (1) | PT2791136E (ar) |
| RS (1) | RS54288B1 (ar) |
| RU (1) | RU2632464C1 (ar) |
| SG (1) | SG11201402820SA (ar) |
| SI (1) | SI2791136T1 (ar) |
| TN (1) | TN2014000254A1 (ar) |
| UA (1) | UA112096C2 (ar) |
| UY (1) | UY34515A (ar) |
| WO (1) | WO2013087579A1 (ar) |
| ZA (1) | ZA201404031B (ar) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015000308A2 (pt) * | 2012-07-10 | 2017-06-27 | Bayer Pharma AG | método para preparo de triazolopiridinas substituídas |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
| US20160128988A1 (en) * | 2013-06-11 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| US9586958B2 (en) * | 2013-06-11 | 2017-03-07 | Bayer Pharma Aktiengesellschaft | Prodrug derivatives of substituted triazolopyridines |
| EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| US10586930B2 (en) * | 2014-05-19 | 2020-03-10 | Udc Ireland Limited | Fluorescent organic light emitting elements having high efficiency |
| MA41136A (fr) * | 2014-12-09 | 2017-10-17 | Bayer Pharma AG | Composés pour le traitement d'un cancer |
| US10485880B2 (en) | 2014-12-15 | 2019-11-26 | Bayer Pharma Aktiengesellschaft | Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies |
| CN105985241A (zh) * | 2015-01-27 | 2016-10-05 | 邵阳学院 | α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用 |
| JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ） |
| EP3313521A1 (de) | 2015-06-23 | 2018-05-02 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| TW201800408A (zh) | 2016-06-15 | 2018-01-01 | 拜耳製藥公司 | Mps-1抑制劑 |
| CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
| US10968216B2 (en) | 2016-10-27 | 2021-04-06 | Bayer Aktiengesellschaft | 4,5-annulated 1,2,4-triazolones |
| US11660351B2 (en) | 2016-12-21 | 2023-05-30 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| CN106831555B (zh) * | 2017-01-22 | 2019-09-24 | 中国农业大学 | 吡啶酰胺类化合物及其制备方法与应用 |
| KR102668688B1 (ko) | 2018-07-23 | 2024-05-24 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| WO2020161257A1 (en) | 2019-02-07 | 2020-08-13 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
| KR102661468B1 (ko) | 2019-02-15 | 2024-04-30 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 전자 장치 |
| KR102897919B1 (ko) | 2019-11-14 | 2025-12-09 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 장치 |
| EP4486350A1 (en) * | 2022-03-04 | 2025-01-08 | SillaJen, Inc. | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US6693116B2 (en) * | 2001-10-08 | 2004-02-17 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| AU2004275694B2 (en) | 2003-06-30 | 2008-03-06 | Bizbiotech Co., Ltd. | Compounds, compositions and methods |
| WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| AU2007291190A1 (en) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| AU2008277628B2 (en) | 2007-07-18 | 2012-03-15 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| CN103298814A (zh) | 2007-08-23 | 2013-09-11 | 阿斯利康(瑞典)有限公司 | 作为治疗增殖性疾病的ttk/mps1抑制剂的2-苯胺基嘌呤-8-酮 |
| CA2691448A1 (en) | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2222674B8 (en) | 2007-11-27 | 2016-01-06 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
| WO2010092015A1 (en) | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
| EA201101188A1 (ru) | 2009-02-13 | 2012-04-30 | Фовеа Фармасьютикалз | [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы |
| WO2010124826A1 (en) | 2009-04-29 | 2010-11-04 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazoquinoxalines |
| CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343294A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| PH12012501381A1 (en) | 2010-01-15 | 2012-10-22 | Janssen Pharmaceuticals Inc | Novel substituted bicyclic triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| JP2011246389A (ja) * | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体 |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| DK2699575T3 (da) * | 2011-04-21 | 2015-06-22 | Bayer Ip Gmbh | Triazolopyridiner |
-
2012
- 2012-10-12 UA UAA201407687A patent/UA112096C2/uk unknown
- 2012-12-10 ES ES12805516.7T patent/ES2550677T3/es active Active
- 2012-12-10 EP EP12805516.7A patent/EP2791136B1/en active Active
- 2012-12-10 PL PL12805516T patent/PL2791136T3/pl unknown
- 2012-12-10 US US14/362,836 patent/US9663510B2/en not_active Expired - Fee Related
- 2012-12-10 PE PE2014000944A patent/PE20141597A1/es not_active Application Discontinuation
- 2012-12-10 DK DK12805516.7T patent/DK2791136T3/en active
- 2012-12-10 MX MX2014007057A patent/MX2014007057A/es unknown
- 2012-12-10 KR KR1020147019041A patent/KR20140105552A/ko not_active Withdrawn
- 2012-12-10 CA CA2858683A patent/CA2858683A1/en not_active Abandoned
- 2012-12-10 AP AP2014007731A patent/AP4017A/en active
- 2012-12-10 RS RS20150663A patent/RS54288B1/sr unknown
- 2012-12-10 AU AU2012350751A patent/AU2012350751B2/en not_active Ceased
- 2012-12-10 HU HUE12805516A patent/HUE025937T2/en unknown
- 2012-12-10 BR BR112014014184A patent/BR112014014184A2/pt not_active Application Discontinuation
- 2012-12-10 PT PT128055167T patent/PT2791136E/pt unknown
- 2012-12-10 SI SI201230337T patent/SI2791136T1/sl unknown
- 2012-12-10 JP JP2014546446A patent/JP6181664B2/ja not_active Expired - Fee Related
- 2012-12-10 SG SG11201402820SA patent/SG11201402820SA/en unknown
- 2012-12-10 WO PCT/EP2012/074978 patent/WO2013087579A1/en not_active Ceased
- 2012-12-10 HR HRP20151103TT patent/HRP20151103T1/hr unknown
- 2012-12-10 RU RU2014128465A patent/RU2632464C1/ru not_active IP Right Cessation
- 2012-12-10 CN CN201280069310.8A patent/CN104114552B/zh not_active Expired - Fee Related
- 2012-12-11 JO JOP/2012/0375A patent/JO3111B1/ar active
- 2012-12-11 AR ARP120104640A patent/AR089143A1/es unknown
- 2012-12-12 UY UY0001034515A patent/UY34515A/es not_active Application Discontinuation
-
2014
- 2014-06-02 IL IL232930A patent/IL232930A/en not_active IP Right Cessation
- 2014-06-03 ZA ZA2014/04031A patent/ZA201404031B/en unknown
- 2014-06-10 PH PH12014501319A patent/PH12014501319A1/en unknown
- 2014-06-10 MA MA37115A patent/MA35826B1/fr unknown
- 2014-06-11 TN TNP2014000254A patent/TN2014000254A1/en unknown
- 2014-06-12 CO CO14127883A patent/CO6980657A2/es unknown
- 2014-06-12 CL CL2014001546A patent/CL2014001546A1/es unknown
- 2014-06-12 CR CR20140275A patent/CR20140275A/es unknown
- 2014-06-12 GT GT201400111A patent/GT201400111A/es unknown
- 2014-06-12 CU CU2014000068A patent/CU20140068A7/es unknown
- 2014-06-12 EC ECIEPI20144812A patent/ECSP14004812A/es unknown
- 2014-06-12 DO DO2014000133A patent/DOP2014000133A/es unknown
-
2015
- 2015-10-23 CY CY20151100951T patent/CY1116958T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3111B1 (ar) | ترايازولوبيريدينات مستبدلة واستخدامها كمثبطات ttk | |
| JO3040B1 (ar) | ترايازولوبيريدينات | |
| TN2012000265A1 (en) | Triazolopyridines | |
| TN2012000595A1 (en) | Substituted triazolopyridines | |
| PH12016501581A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| PH12014500501A1 (en) | Amino-substituted imidazopyridazines | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| PH12016500054A1 (en) | Substituted pyrazolo-pyridinamines | |
| PH12015502747A1 (en) | Novel compounds for the treatment of cancer | |
| UA110822C2 (uk) | Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів | |
| PH12015500061A1 (en) | Method for preparing substituted triazolopyridines | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| TN2013000426A1 (en) | Triazolopyridines | |
| SA112330437B1 (ar) | تركيبات دوائية محتوية على عامل منوم او مخدر وطريقة تحضيرها | |
| UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao |